Alnylam Pharmaceuticals (ALNY) has made notable moves recently. Following the initiation of the ZENITH Phase 3 trial and the release of HELIOS-B data, the company adjusted its valuation, its television advertisement was withdrawn after Trump's crackdown on drug industry spots, signifcant decrease of stake by Wealth Enhancement, and secured a hefty credit agreement of $500m. There's speculations around announcements of special dividends as it's trading dynamics indicates. An FDA warning led to the pulling of an ad, and progress in RNAi drug discovery was made possible through joining the Genomic Alliance. The reported $492M Amvuttra sales has resulted in raised revenue guidance for 2025. While top executives are selling their shares, there's an impressive growth in Amvuttra since its launch. The company is seen lobbying for positive coverage and its legal battle with Moderna over patent law is on going. Notably, FDA's approval for Amvuttra, the first RNAi therapeutic drug, appears to be a major breakthrough.
Alnylam Pharmaceuticals News Analytics from Mon, 24 Feb 2025 08:00:00 GMT to Sat, 04 Oct 2025 21:06:59 GMT -
Rating 6
- Innovation 8
- Information 8
- Rumor 4
